STAT+: Vaxcyte claims success in bid to beat Pfizer and Merck in lucrative vaccine market

Vaxcyte stock experienced a remarkable 51.3% surge in pre-market trading following the release of positive topline data from its pivotal adult Phase 3 trial, OPUS-1, examining its VAX-31 vaccine candidate. The trial, which included 4,047 participants across around 30 U.S. sites, showcased VAX-31's successful performance in all co-primary immunogenicity endpoints.

Every serotype shared with Pfizer's Prevnar 20 and Merck's Capvaxive met the noninferiority threshold, while the three unique serotypes of VAX-31 and cross-reactive serotype 20B demonstrated superiority. This strong data performance led to swift analyst enthusiasm, with Guggenheim raising its price target on PCVX to $125 from $116 while maintaining its Buy rating.

The positive results also fueled a short squeeze dynamic, as the stock's short interest had been roughly 10% of the float, a level that typically intensifies upward moves when significant clinical events turn favorable. The broader market, however, remained relatively subdued, with the S&P 500, Dow Jones, and NASDAQ all modestly lower on the day, indicating that Vaxcyte's surge is primarily driven by company-specific news rather than macroeconomic factors.

Industry peers Pfizer and Merck, whose vaccines were used as benchmarks in the OPUS-1 trial, now face a more competitive landscape. The company's upcoming Biologics License Application submission, scheduled for the first half of 2028, and anticipated results from OPUS-2 and OPUS-3 adult Phase 3 trials in the first half of 2027 further de-risk the path to commercialization for Vaxcyte.